...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta oncologica. >Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
【24h】

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen

机译：对两年和五年佐莫昔芬的随机试验中第二原发性癌症发生率的长期影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Tamoxifen is a well established treatment for breast cancer, but its long-term effects on the incidence of secondary cancers are not fully evaluated.Material and methods: We have studied 4128 postmenopausal patients with early stage breast cancer who were alive and free of breast cancer recurrence after two years of tamoxifen, and who were randomized to receive totally two or five years of therapy.Results: Compared to patients randomized to two years of tamoxifen the incidence of contralateral breast cancer [hazard ratio (HR) 0.73; 95% CI 0.56-0.96] and of lung cancer (HR 0.45; 95% CI 0.27-0.77), especially squamous cell and small cell lung cancer, were reduced in the five-year group, and similar results were seen when restricting the analysis to the 10-year period after treatment stopped. An increased incidence of endometrial cancer was observed in the five-year group, but the excess risk decreased over time.Conclusion: Further studies of the effects of tamoxifen on the risk of different histological types of lung cancer are needed.
机译：背景：Tamoxifen是乳腺癌的成熟治疗，但它对次生癌症发生率的长期影响未得到充分评估。两年后乳腺癌复发，并随机接受两年或五年的治疗。结果：与随机患者患者相比，对侧乳腺癌的发生率[危险比（HR）0.73; 95％CI 0.56-0.96]和肺癌（HR 0.45; 95％CI 0.27-0.77），尤其是鳞状细胞和小细胞肺癌，在五年组中降低，并且在限制分析时看到类似的结果治疗后的10年期间。在五年组中观察到子宫内膜癌的发病率增加，但随着时间的推移，风险过剩下降。结论：需要进一步研究他莫昔芬对不同组织学类型的肺癌风险的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号